Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label ixazomib + daratumumab + dexamethasone in relapsed/refractory multiple myeloma
2017-003977-32Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals, Inc
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib, daratumumab and dexamethasone in multiple myeloma (MM), sponsored by Millennium Pharmaceuticals, Inc. Primary endpoint: Very good partial response (VGPR) or better rate. Started Apr 2018; status: completed.
02
Drugs
ixazomibdaratumumabdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-003977-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003977-32.